Insmed registers Phase 1 trial on brensocatib's effect on midazolam metabolism
A new trial will examine whether brensocatib induces CYP3A enzyme activity, which could affect how the body processes midazolam.
Insmed Incorporated listed one new Phase 1 study this week, not yet recruiting.
- "A Phase 1, Open-Label, Fixed Sequence, Drug-Drug Interaction Study Assessing the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics of Midazolam in Healthy Participants" (NCT07859007) is designed to measure how repeated dosing of brensocatib changes the pharmacokinetics of a single oral dose of midazolam in healthy men and women.1 The study plans to enroll 26 participants1 and has an estimated start date of October 29, 2026, with primary completion estimated for November 25, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.